|Richard J. Meelia|
Mr. Meelia joined our Board and assumed the role of Chairman in 2011. From July 2007 until his retirement in July 2011, Mr. Meelia served as Chairman, President and Chief Executive Officer of Covidien plc, a global healthcare products company, following its separation from Tyco International in June 2007. Prior to that separation, Mr. Meelia served in a variety of senior leadership roles, including Chief Executive Officer and President of Tyco Healthcare. Mr. Meelia previously served as a director of Haemonetics from 2005 to 2009.
Director, President and Chief Executive Officer
Mr. Simon is President and Chief Executive Officer of Haemonetics. He joined Haemonetics and our Board in May 2016. Previously, Mr. Simon served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon was a consultant with McKinsey & Company beginning in 1993 and was the Lead Partner for McKinsey & Company’s strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the Company’s business and markets. Together with management and the Board, he was the co-architect of the strategic plan that the Company is now implementing.
|Robert E. Abernathy|
Mr. Abernathy joined our Board in 2017 and is a member of both the Compensation Committee and the Technology Committee. Mr. Abernathy served as a Chairman and Chief Executive Officer of Halyard Health Inc., a medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Previously, he held roles of increasing responsibility with Kimberly-Clark Corporation, including President of Kimberly Clark’s Global Healthcare business.
|Catherine M. Burzik|
Ms. Burzik joined our Board in 2016 and is Chair of the Technology Committee and a member of the Audit Committee. Ms. Burzik’s previous leadership experience includes serving as President and Chief Executive Officer of Kinetic Concepts, Inc., a global medical device company, from 2005 until the company’s sale in 2012, serving as President of Applied Biosystems Group and holding senior executive positions at Eastman Kodak and Johnson & Johnson, including Chief Executive Officer and President of Kodak Health Imaging Systems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company.
|Charles J. Dockendorff|
Mr. Dockendorff joined our Board in 2014 and is Chair of the Audit Committee. Mr. Dockendorff served as Executive Vice President and Chief Financial Officer at Covidien plc, a global healthcare company, and its predecessor Typo Healthcare, from 1995 until his retirement in 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller five years later.
|Ronald G. Gelbman|
Mr. Gelbman joined our Board in 2000 and is Chair of the Governance and Compliance Committee and a member of the Audit Committee. He served as interim Chief Executive Officer of Haemonetics from September 2015 through May 2016. Mr. Gelbman retired from Johnson & Johnson, a global healthcare company, in April 2000, after serving in a variety of senior executive roles, including as a member of the executive committee and as Worldwide Chairman of the Pharmaceuticals, Health Systems and Diagnostics Group.
|Pedro P. Granadillo|
Mr. Granadillo joined our Board in 2004 and is Chair of the Compensation Committee and a member of the Governance and Compliance Committee. Mr. Granadillo retired from Eli Lilly and Company, a global pharmaceutical company, in 2004 after 34 years of dedicated service, including 13 years in Europe. Mr. Granadillo held several senior leadership roles at Eli Lily and Company, including as a member of the executive committee and as a Senior Vice President with world-wide responsibility for manufacturing, quality and human resources.
|Mark W. Kroll, Ph.D.|
Dr. Kroll joined our Board in 2006 and is a member of both the Compensation Committee and the Technology Committee. He currently serves as an Adjunct Full Professor of Biomedical Engineering at the University of Minnesota. From 1995 until his retirement in 2005, Dr. Kroll held a variety of executive leadership positions at St. Judge Medical, Inc., a global medical device company, including as Senior Vice President and Chief Technology Officer for the Cardiac Rhythm Management division and as Vice President of the Tachycardia Business division. Dr. Kroll has more than 25 years’ experience with cardiovascular devices and instrumentation and is the named inventor of more than 350 U.S. patents as well as numerous international patents.
|Ellen M. Zane|
Ms. Zane joined our Board in 2018 and is a member of both the Governance and Compliance Committee and the Compensation Committee. Ms. Zane currently serves as Vice Chair of the Board of Trustees of Tufts Medical Center and Floating Hospital for Children in Boston, Massachusetts, where she served as President and Chief Executive Officer from 2004 to 2011. Previously, Ms. Zane served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard affiliated Massachusetts General Hospital and Brigham and Women's Hospital, and as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane previously served as a director of Haemonetics from 2012 to 2016.